EUS-FNA predicts 5-year survival in pancreatic endocrine tumors
Fátima A. F. Figueiredo, MD, PhD, Marc Giovannini, MD, PhD, Genevieve Monges, MD, PhD, Erwan Bories, MD, Christian Pesenti, MD, Fabrice Caillol, MD, Jean Robert Delpero, MD, PhD
Marseille, France

Background: Pancreatic endocrine tumors (PETs) differ in clinical behavior and prognosis. Determination of malignant potential through specimens obtained by EUS-FNA can help in the management of these patients.

Objective: To determine the value of EUS-FNA for diagnosing PETs and for classifying their underlying malignant potential based on the World Health Organization (WHO) classification.

Design: Single-center, retrospective, cohort study.

Setting: Tertiary referral hospital.

Patients: This study involved 86 consecutive patients (44 men, mean age 58 ± 14 years) who had been diagnosed with PETs and submitted to EUS-FNA from January 1999 to August 2008.

Intervention: EUS-FNA of a pancreatic mass and/or a metastasis site. Immunohistochemistry on microbiopsies or on monolayer cytology was routinely used. The lesions were classified as recommended by the WHO.

Main Outcome Measurements: EUS-FNA sensitivity and 5-year survival rate.

Results: Overall, in 90% (77 of 86) of patients in this study, PET was diagnosed with EUS-FNA. The sensitivity did not vary with tumor size, type, location, or the presence of hormonal secretion. Of 86 patients, 30 (35%) were submitted to surgical resection. The kappa correlation index between the WHO classification obtained by EUS-FNA and by surgery was 0.38 (P = .003). Major discrepancies were found in the group of patients diagnosed with endocrine tumor of uncertain behavior by EUS-FNA, because 72% turned out to have well-differentiated endocrine carcinoma. Sixteen patients (27%) died during a mean follow-up period of 34 ± 27 months. The 5-year survival rates were 100% for endocrine tumors, 68% for well-differentiated endocrine carcinomas, and 30% for poorly differentiated endocrine carcinomas (P = .008, log-rank test).

Limitations: Retrospective design, selection bias, and small sample size.

Conclusions: This largest single-center experience to date demonstrated the accuracy of EUS-FNA in diagnosing and determining the malignant behavior of PETs. EUS-FNA findings predict 5-year survival in patients with PETs. (Gastrointest Endosc 2009;70:907-14.)
classification is based on tumor size, histology, and proliferative indices. Some recent publications have focused on the application of this classification in surgical specimens.5,7,10

EUS and EUS-FNA have become the preferred modalities for localizing and diagnosing PETs. They are useful for distinguishing PET from adenocarcinoma and for localizing tumors not imaged by conventional studies.11 Anderson et al12 correctly localized tumors with EUS in 93% of cases. Several authors have shown sensitivity and accuracy rates greater than 80% for EUS-FNA.10,13,14 These studies, however, did not apply the recently proposed WHO classification to specimens obtained by EUS-FNA.

Recognition of the underlying malignant behavior of GI endocrine tumors has led to a much greater aggressiveness in their treatment, with both medical and surgical modalities. The outcomes emerging from this more aggressive approach to treatment are improved quality of life and 5-year survival (from 40% to 82% for metastatic PETs).15,16 Despite the small number of cases, Sellner et al17 demonstrated the clinical importance of distinguishing between well-differentiated and poorly differentiated endocrine carcinomas. Tumor extension, metastases, secretor profile, and degree of differentiation should be determined as far as possible before treatment is planned.18 Determination of tumor malignant potential at an early stage of investigation, through specimens obtained by EUS-FNA, would be of great importance in the stratification, treatment, and follow-up of patients with PET.

The aim of this study was to determine the value of EUS-FNA for the diagnosis of PETs and for classifying the underlying malignant potential of these tumors based on the proposed WHO classification.8,9

METHODS

This was a retrospective study. A detailed review of the medical records from January 1999 to August 2008 was performed to identify consecutive patients who had been diagnosed with PET and submitted to EUS-FNA, at the Institute Paoli-Calmettes, Marseille, France. The study protocol was conducted in accordance with the ethical principles and guidance of the Helsinki Declaration. The study was approved by the local ethics committee.

The diagnosis of PET was established by evaluation of microbiopsies or monolayer cytology obtained by EUS-FNA and/or histopathological evaluation obtained by surgical resection of a pancreatic mass and/or a metastasis site. All diagnoses were confirmed by immunohistochemistry. Demographic data, clinical and EUS findings, and cytology and histopathological results were reviewed.

EUS procedures were performed by experienced endoscopists who used linear-array echoendoscopes (FG36X or EG38UT, Pentax Europe Ltd., Hamburg, Germany) with an ultrasound platform (Hitachi 6500 or 8500, Hitachi Medical Systems GmbH, Wiesbaden, Germany). EUS-FNA was performed by using a 22-gauge FNA needle (Echotip, Cook Endoscopy, Winston-Salem, NC). Antibiotics were not administered prophylactically.

An immediate screening at the time of EUS-FNA was not performed. Direct smears were prepared by the endoscopist and were stained with May-Grunwald-Giemsa stain on air dried slides. ThinPrep preparation (monolayer cytology, Cytyc Corp., Boston, Mass) was used in all cases. Cell block material, fixed in 10% neutral buffered formalin, was collected at the reception of the aspirated material. Hematoxylin-eosin staining was performed on cell block preparations and on monolayer cytology slides. Endocrine differentiation was confirmed immunohistochemically on cell block preparations or in the absence of material on cell blocks on monolayer cytology specimens. Immunohistochemical analysis was performed according to the streptavidin-biotin technique. The antibodies used were synaptophysin (polyclonal, prediluted, Dako, France) and chromogranin A (clone LK2H10, 1/200, Beckman Coulter, France). In addition to the histological differentiation grade, p53 (clone DO-7, 1/10, Dako, France) and Ki-67 (clone Mib-1, prediluted, Dako, France) labeling indices were amended when sufficient tumor tissue was available.

Blocks of surgical specimens were generally fixed in formalin. Routine diagnostic sections were stained with hematoxylin-eosin. Endocrine differentiation was confirmed immunohistochemically by using antibodies against synaptophysin and chromogranin A. Antibodies p53 and Ki-67 were used. Where there had been evidence of ectopic hormone secretion, immunostaining was performed for the appropriate hormones.

The final diagnosis and differentiation of PET was established by a single experienced pathologist. The lesions were classified according to the WHO recommendation as shown in Table 1.8,9 The WHO classification obtained by EUS-FNA was compared with that obtained by surgical resection when both were available.

The statistical analysis was done with SPSS 11.0 (SPSS Inc, Chicago, IL) software. The categorical variables were
expressed by their absolute (n) and relative frequency (%) and compared by using the $\chi^2$ test or Fisher exact test. The continuous variables were expressed by mean and standard deviation and compared by using a $t$-test or Mann-Whitney test. Sensitivity and specificity of EUS-FNA for diagnosing and classifying PET was obtained. Overall survival analysis was performed by using the Kaplan-Meier method and log-rank test. Single-factor Cox regression analysis was conducted for tumor grading. A $P$ value < .05 was considered statistically significant; all tests were 2-sided.

RESULTS

Eighty-six patients (44 men, mean age 58 ± 14 years) with a diagnosis of PET were identified. Of these patients, 12 (14%) were diagnosed with F-PET. The mean size of the lesions was 29 ± 20 mm (range 5-100 mm). Fourteen (16%) lesions were ≤10 mm. Forty-five (52%) tumors were located in the head/uncinate, 26 (30%) in the body, and 15 (18%) in the tail of the pancreas. Eight (9%) lesions had a cystic component. There were no procedure-related complications.

Seventy-eight patients (91%) underwent EUS-FNA of the pancreatic mass, and 15 (17%) underwent EUS-FNA of a metastasis site. Of these, 67 (78%) were diagnosed with PET at the first EUS-FNA. Eight (9%) patients had the diagnosis made at a second EUS-FNA and 2 (2.3%) at a third EUS-FNA. Overall, 90% (77 of 86) of patients had the diagnosis of PET established by EUS-FNA. There were no significant differences in the sensitivity of EUS-FNA according to tumor size, location, cystic component, or excess hormone production (Table 2).

Based on the results of EUS-FNA, patients were classified as follows: 15 (17.4%) BBWDET, 15 (17.4%) UBWDET, 21 (24.4%) WDEC, and 26 (30.2%) PDEC (Figs. 1 and 2). Nine (10.5%) patients had inconclusive results by EUS-FNA.

Seventy-eight patients (91%) underwent EUS-FNA of the pancreatic mass, and 15 (17%) underwent EUS-FNA of a metastasis site. Of these, 67 (78%) were diagnosed with PET at the first EUS-FNA. Eight (9%) patients had the diagnosis made at a second EUS-FNA and 2 (2.3%) at a third EUS-FNA. Overall, 90% (77 of 86) of patients had the diagnosis of PET established by EUS-FNA. There were no significant differences in the sensitivity of EUS-FNA according to tumor size, location, cystic component, or excess hormone production (Table 2).

Based on the results of EUS-FNA, patients were classified as follows: 15 (17.4%) BBWDET, 15 (17.4%) UBWDET, 21 (24.4%) WDEC, and 26 (30.2%) PDEC (Figs. 1 and 2). Nine (10.5%) patients had inconclusive results by EUS-FNA.

Seventy-eight patients (91%) underwent EUS-FNA of the pancreatic mass, and 15 (17%) underwent EUS-FNA of a metastasis site. Of these, 67 (78%) were diagnosed with PET at the first EUS-FNA. Eight (9%) patients had the diagnosis made at a second EUS-FNA and 2 (2.3%) at a third EUS-FNA. Overall, 90% (77 of 86) of patients had the diagnosis of PET established by EUS-FNA. There were no significant differences in the sensitivity of EUS-FNA according to tumor size, location, cystic component, or excess hormone production (Table 2).

Based on the results of EUS-FNA, patients were classified as follows: 15 (17.4%) BBWDET, 15 (17.4%) UBWDET, 21 (24.4%) WDEC, and 26 (30.2%) PDEC (Figs. 1 and 2). Nine (10.5%) patients had inconclusive results by EUS-FNA.

Based on the results of EUS-FNA, patients were classified as follows: 15 (17.4%) BBWDET, 15 (17.4%) UBWDET, 21 (24.4%) WDEC, and 26 (30.2%) PDEC (Figs. 1 and 2). Nine (10.5%) patients had inconclusive results by EUS-FNA.

Seventy-eight patients (91%) underwent EUS-FNA of the pancreatic mass, and 15 (17%) underwent EUS-FNA of a metastasis site. Of these, 67 (78%) were diagnosed with PET at the first EUS-FNA. Eight (9%) patients had the diagnosis made at a second EUS-FNA and 2 (2.3%) at a third EUS-FNA. Overall, 90% (77 of 86) of patients had the diagnosis of PET established by EUS-FNA. There were no significant differences in the sensitivity of EUS-FNA according to tumor size, location, cystic component, or excess hormone production (Table 2).

Based on the results of EUS-FNA, patients were classified as follows: 15 (17.4%) BBWDET, 15 (17.4%) UBWDET, 21 (24.4%) WDEC, and 26 (30.2%) PDEC (Figs. 1 and 2). Nine (10.5%) patients had inconclusive results by EUS-FNA.

Based on the results of EUS-FNA, patients were classified as follows: 15 (17.4%) BBWDET, 15 (17.4%) UBWDET, 21 (24.4%) WDEC, and 26 (30.2%) PDEC (Figs. 1 and 2). Nine (10.5%) patients had inconclusive results by EUS-FNA.

Based on the results of EUS-FNA, patients were classified as follows: 15 (17.4%) BBWDET, 15 (17.4%) UBWDET, 21 (24.4%) WDEC, and 26 (30.2%) PDEC (Figs. 1 and 2). Nine (10.5%) patients had inconclusive results by EUS-FNA.
procedures available (Table 3). The kappa correlation index between the 2 classifications was 0.38, \( P = .003 \). The only major discrepancy was found in the 6 patients classified as UBWDET by EUS-FNA. Five (71%) of them turned out to have WDEC. Of the 9 patients with inconclusive results obtained by EUS-FNA, 6 underwent surgery. One patient had BBWDET, and 5 had WDEC. We had follow-up data for 60 patients. Sixteen patients (27%) died during a mean follow-up period of 34 ± 27 months (range 3-108 months). The survival analysis classified according to the WHO classification indicated a significantly poorer survival rate for patients who had PDEC (Table 4 and Fig. 3). The 5-year survival rates according to the WHO classification were 100% for BBWDET and UBWDET, 68% for WDEC, and 30% for PDEC (\( P = .008 \), log-rank test). When only PET-related deaths (15 patients) were considered as events for survival analysis, the 5-year survival rates were of 100%, 68%, and 40%, respectively (\( P = .01 \), log-rank test).

Cox regression analysis was performed but did not include BBWDET and UBWDET, because of an absence of any events, which excluded these categories from calculation within this model. This analysis confirmed an increased risk of reduced survival for patients with PDEC. Although not statistically significant, the relative risk of death trends toward an increase to approximately threefold for PDEC compared to WDEC (hazard ratio = 2.8, \( P = .09 \), 95% CI, 0.8-9.5).

**DISCUSSION**

Recognition of the underlying malignant behavior of PETs in the setting of a slow rate of growth has led to a much greater aggressiveness in their treatment and has improved the 5-year survival rate. 15,16 Our study is the largest single-center experience to date and demonstrates the success of EUS-FNA in accurately diagnosing and determining the malignant potential of PET. Furthermore, EUS-FNA added prognostic information by predicting 5-year survival. This may be very important in directing the management of patients with PETs.
The study population was composed of 86 patients with PET, seen during a 9-year period. Our sample was predominantly of patients with NF-PET greater than 10 mm and with fairly advanced disease. It should be noted that our institution is a cancer center considered reference for taking care of patients with PET in the south of France. Therefore, a selection bias could be present.

There are few data on the accuracy of EUS-FNA in diagnosing PET. Our overall sensitivity rate of EUS-FNA for diagnosing PET was high (90%). We would like to emphasize that such a high sensitivity could be reached only with the repetition of EUS-FNA in negative results. Although we cannot discard a type II error due to a small sample size in our study, we did not find any difference in sensitivity of EUS-FNA between F-PET versus NF-PET, solid versus cystic tumors, lesions ≤ and > 10 mm, and in tumors in different locations.

Ardengh et al\textsuperscript{13} reported an overall EUS-FNA sensitivity of 83% for diagnosing PET in 30 patients, with a decrease to 75% in the 11 patients with negative abdominal imaging. Recently, Pais et al\textsuperscript{14} presented data, in an abstract form, reporting an overall sensitivity of EUS-FNA of 84% for diagnosing PET in 66 patients, being 78% for F-PET, 89% for NF-PET, and a lower rate in tumors smaller than 15 mm in diameter (62%). Our better results probably reflect the experience of a reference center where 4 experienced endosonographers did the EUS-FNAs and only a single, highly experienced and dedicated pathologist performed all analysis. Additional factors were the use of the ThinPrep technique (monolayer cytology), immunohistochemistry on microbiopsies or on monolayer cytology routinely, and persistence (to repeat EUS-FNA in negative cases). Therefore, the results may be generalizable only to institutions in which this expertise is available.

Although EUS-FNA is often used for diagnosing PET, as far as we know, there are no data on its accuracy in determining the malignant potential of PETs and in applying the WHO classification. In this study, there was a fair correlation between the WHO classification obtained by EUS-FNA and that obtained by surgery in the 24 patients who had records on both procedures available. All 10 patients classified as having an endocrine carcinoma by EUS-FNA had the diagnosis confirmed by surgery. Among them, EUS-FNA was able to correctly classify 80% of the

---

**Figure 2.** Poorly differentiated endocrine carcinoma (Group III of the WHO classification). **A**, Microbiopsies: cohesive sheets of round, uniform, small cells, high mitotic rate (H&E, orig. mag. ×200). **B**, Cytoplasmic immunohistochemical positivity with chromogranin A antibody (orig. mag. ×200). **C**, Nuclear positivity in a high number of tumor cells with Ki-67 immunodetection (orig. mag. ×200).
WDEC and 60% of the PDEC cases. Of 7 patients with BBWDET by EUS-FNA, only 1 (14%) had a change of diagnosis to WDEC after surgery. The problematic group for EUS-FNA was the UBWDET group, as 5 of 7 (72%) patients turned out to have WDEC. Care should be exercised when this diagnosis is obtained by EUS-FNA.

According to Sellner et al,17 the better outcome of surgical treatment of nonfunctioning neuroendocrine pancreatic carcinoma, compared to that of ductal pancreatic cancer, was confined to well-differentiated lesions. The outcome of undifferentiated endocrine lesions was as poor as for ductal pancreatic cancer. Although well and poorly differentiated lesions did not differ in terms of the T categories, poorly differentiated lesions had more node involvement (66% vs 20%), more metastasis (40% vs 17%), and lower 5-year survival rates (0% vs 100%) than did well-differentiated lesions.17 This different pattern of the 2 subsets of nonfunctioning neuroendocrine pancreatic cancer supports the high diagnostic and predictive value of the WHO classification in surgical specimens.

The possibility of applying the WHO classification in EUS-FNA specimens demonstrated in this study is of special interest for those obtaining prognostic information before deciding on the type of management. We started incorporating the WHO classification in the management of patients in our unit. Patients with BBWDET lesions equal or less than 1 cm in size are monitored at 12-month intervals by EUS. Patients with BBWDET lesions from 1 to 2 cm in size either can be monitored at 6-month intervals or surgical treatment can be deemed appropriate. Patients with UBWDET, WDEC, and PDEC lesions equal or less than 2 cm in size are monitored at 6-month intervals by EUS. Patients with UBWDET, WDEC, and PDEC lesions from 2 to 4 cm in size either can be monitored at 3-month intervals or surgical treatment can be deemed appropriate. Patients with PDEC lesions equal or more than 4 cm in size or with other types of lesions are referred for surgical treatment.

### TABLE 3. Comparison between World Health Organization classification obtained by EUS-FNA and surgery in the 24 patients who had records of both procedures available

<table>
<thead>
<tr>
<th>WHO classification by surgery</th>
<th>Group I</th>
<th>Group II</th>
<th>Group III</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO classification by EUS-FNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I BBWDET</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>II UBWDET</td>
<td>2</td>
<td>5</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>III WDEC</td>
<td>4</td>
<td>1</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>PDEC</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>7</td>
<td>1</td>
<td>13</td>
<td>3</td>
</tr>
</tbody>
</table>

WHO, World Health Organization; BBWDET, well-differentiated endocrine tumor of probable benign behavior; UBWDET, well-differentiated endocrine tumor of uncertain behavior; WDEC, well-differentiated endocrine carcinoma; PDEC, poorly differentiated endocrine carcinoma.

Kappa correlation index 0.38, \(P = .003\).

### TABLE 4. Mean survival and 5-year survival rates for patients with PETs, according to the World Health Organization classification

<table>
<thead>
<tr>
<th>WHO classification</th>
<th>No. of deaths (%)</th>
<th>Survival time in months, mean ± SD (range), 95% CI</th>
<th>5-year survival rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>16 of 60 (27)</td>
<td>69 ± 7 (56-82)</td>
<td>60</td>
</tr>
<tr>
<td>BBWDET</td>
<td>0 of 11 (0)</td>
<td>Cannot be computed</td>
<td>100</td>
</tr>
<tr>
<td>UBWDET</td>
<td>0 of 8 (0)</td>
<td>Cannot be computed</td>
<td>100</td>
</tr>
<tr>
<td>WDEC</td>
<td>4 of 17 (24)</td>
<td>66 ± 7 (53-79)</td>
<td>68</td>
</tr>
<tr>
<td>PDEC</td>
<td>9 of 16 (56)</td>
<td>42 ± 9 (24-61)</td>
<td>30</td>
</tr>
<tr>
<td>Inconclusive FNA</td>
<td>3 of 8 (38)</td>
<td>52 ± 10 (33-72)</td>
<td>52</td>
</tr>
<tr>
<td>P value</td>
<td>.006*</td>
<td>.008†</td>
<td></td>
</tr>
</tbody>
</table>

PET, Pancreatic endocrine tumor; WHO, World Health Organization; BBWDET, well-differentiated endocrine tumor of probable benign behavior; UBWDET, well-differentiated endocrine tumor of uncertain behavior; WDEC, well-differentiated endocrine carcinoma; PDEC, poorly differentiated endocrine carcinoma; CI, confidence interval.

*χ² test.
†Log-rank test.
by EUS or submitted to an organ-sparing strategy for the pancreas (enucleation). All of the other lesions are resected when possible. We complement treatment with somatostatin analogs or chemotherapy, depending on differentiation of endocrine carcinoma.

Another potential advantage of using the WHO classification in EUS-FNA specimens is the possibility of comparison among studies. It has been difficult to compare results from different studies in PET because of a lack of uniformity in the pathologic classification of these tumors or standardization of the minimum criteria for histological diagnosis.2

One of the most striking findings in our study is that 5-year survival can be predicted by EUS-FNA. Similar to the findings of Pape et al,19 the current results demonstrate the prognostic accuracy of the newly proposed WHO classification system for PET. Mortality is seen only in patients classified as WHO groups II and III (endocrine carcinoma). The new classification system provides a valid and powerful tool for prognostic stratification of PET in clinical practice and for research. This prognostic information may help to determine the most appropriate management for patients, because a more aggressive approach improves quality of life and 5-year survival rates for patients with PET.15,16

Some limitations of our study, similar to those of all retrospective studies, is underreporting and missing data. Because ours is a reference center, we probably have a selection bias of more advanced disease. We also lost part of our sample because the records were returned to the referring hospitals. On the other hand, as far as we know, ours is the largest single-center study demonstrating that it is possible to determine the potential malignant behavior of PETs in specimens obtained by EUS-FNA.

In summary, EUS-FNA is a safe and highly accurate technique for diagnosing PET. Our report, which is the largest experience of EUS-FNA in the diagnosis of PET, also identified new trends. It is possible to determine the potential malignant behavior of a PET in specimens obtained by EUS-FNA by applying the WHO classification. EUS-FNA findings predict 5-year survival in patients with PET. This may help to better guide the therapeutic approach for these patients.

ACKNOWLEDGMENT

We acknowledge Dr David Abi-Hanna for his English review.

REFERENCES


Received November 17, 2008. Accepted May 6, 2009.


Reprint requests: Fátima Aparecida Ferreira Figueiredo, MD, PhD, Gastroenterology Department - University of the State of Rio de Janeiro, Rua Humaitá 282 Bl II Ap 1703 Humaitá, Rio de Janeiro, Brazil 22261001.

If you would like to chat with an author of this article, you may contact him at faff@gb1.com.br.

Receive tables of content by e-mail

To receive tables of content by e-mail, sign up through our Web site at www.giejournal.org.

Instructions

Log on and click “Register” in the upper right-hand corner. After completing the registration process, click on “My Alerts” then “Add Table of Contents Alert.” Select the specialty category “Gastroenterology” or type Gastrointestinal Endoscopy in the search field and click on the Journal title. The title will then appear in your “Table of Contents Alerts” list.

Alternatively, if you are logged in and have already completed the Registration process, you may add tables of contents alerts by accessing an issue of the Journal and clicking on the “Add TOC Alert” link.

You will receive an e-mail message confirming that you have been added to the mailing list. Note that tables of content e-mails will be sent when a new issue is posted to the Web.